Completed clincal trials:
- A first in man Phase I study to investigate tolerability and safety of topical LTX-109 in healthy subjects (Study C08-109-01)
- A Phase I/IIa study to evaluate the safety, tolerability and efficacy of topical LTX-109 in subjects nasally colonized with methicillin-resistant/-sensitive Staphylococcus aureus (MRSA/MSSA; Study C10-109-02)
- A Phase IIa pilot study to evaluate the safety, tolerability and efficacy of LTX-109 in patients with uncomplicated, Gram-positive, skin infection (Study C10-109-03)
- A Phase II, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of two doses of LTX-109 (1 % and 2 %) versus placebo in impetigo (Study C12-109-04)